INTRODUCTION
New diagnostic assays are developed to improve current tests or to provide an assay when one is not available. When a new diagnostic assay is developed as a replacement for a current diagnostic test, methods must be found to provide accurate comparative test performance (sensitivity and specificity) data. A common method of evaluation is to simply compare the results of the new assay with those of the test currently in use. This comparison results in quantification of the agreement (concordance) between the two assays but does not address the question of differences in sensitivity or specificity. Sensitivity is defined by the following formula:
test positives x 100 test positives + false negatives and specificity is defined as follows:
test negatives x 100 test negatives + false positives It is clear from these formulas that sensitivity measures false-negative results and specificity quantitates false-positive results (23) .
Much of the difficulty in obtaining accurate test performance data resides in defining a "gold standard" for disease in the above formulas. One such accepted "gold standard" is the transmission of disease from an animal which is test positive to an animal which is test negative. For most experimental designs, transmission data cannot be obtained for every animal tested. Depending on the reasons for developing a new diagnostic assay, concordance data may be a sufficient first step in test evaluation. For example, if a new diagnostic assay is designed solely to provide a more rapid test, concordance data may be sufficient for validation. If a test with improved performance is required, then the best "gold standard" for comparison must be identified and utilized for validation of a new assay. Clearly, when a diagnostic assay is the first test reported for a particular disease, a "gold standard" must be identified which can provide the criteria for test validation. In this context, some recently-developed monoclonal antibody (MAb)-based enzyme-linked immunosorbent assays (ELISAs) are reviewed.
ANTIGEN CAPTURE ENZYME-LINKED IMMUNOSORBENT ASSAY
The primary advantage of the antigen capture ELISA is the ability of this test to detect parasite antigen directly from an animal prior to or during clinical disease. The main component of the antigen capture ELISA is a MAb. The desired characteristics of this MAb are:
-strong binding to the parasite -the ability to attach to an ELISA plate without loss of reactivity -in addition, a second MAb recognizing an epitope other than the MAb which is bound to the ELISA plate is often used as part of the indicator system. Anaplasmosis, a vector-borne haemoparasitic rickettsial disease, is caused by Anaplasma marginale (20) and A. centrale (21) . Clinical disease is characterized by anaemia, weight loss, abortion and death (1), and survivors are lifelong carriers of the rickettsia (19) . Recently, an antigen capture ELISA has been developed for the detection of A. marginale rickettsaemia prior to the onset of clinical disease (22) . The assay sensitivity is 1.1(±0.5)% parasitized erythrocytes. This ELISA uses two MAbs which recognize different epitopes on a major surface protein of A. marginale (22) . These epitopes had previously been shown to be conserved among different A. marginale isolates (17) . The ELISA was validated by testing blood from twenty-four calves before and after experimental infection with A. marginale (22) . This assay was shown to be specific for A. marginale, in that blood samples containing Babesia bovis, B. bigemina, A. ovis and six antigenic variants of Trypanosoma brucei tested negative (22) .
Since this assay discriminates between anaplasmosis and other clinically similar haemoparasitic diseases, it permits diagnosis and treatment of cattle in a critical stage of infection (22) . A primary advantage of this assay is the detection of infected cattle early in the course of disease, when tetracycline therapy is most successful in preventing death (16) .
Cryptosporidiosis (caused by the sporozoan Cryptosporidium parvum) is a common infection of young calves (4) . C. parvum is one of the major causes of neonatal diarrhoea in calves and contributes to significant economic losses in the beef and dairy cattle industries (9) . An antigen capture ELISA which detects Cryptosporidium sp. oocysts in bovine faeces was recently described (3). For capture, the assay uses an immunoglobulin (Ig)M MAb which binds to a 40 kDa oocyst antigen, and uses polyclonal goat anti-oocyst serum in the indicator system (3). The format of this test is illustrated in Figure 1 . 
The assay detects as few as 3 x 10 5 C. parvum oocysts per ml of faeces and does not detect oocysts of Eimeria auburnensis, E. bovis, E. ellipsoidalis or E. zuernii (3). The assay was validated by: a) testing faeces from naturally or experimentally-infected calves from three locations b) comparing the ELISA to indirect immunofluorescence and light microscopic analysis c) following the kinetics of faecal shedding of C. parvum oocysts by experimentallyinfected calves (3).
The utility of this assay is that it is sufficiently sensitive to detect oocysts in animals with clinical signs of disease, as well as in calves which have recovered from diarrhoea but which continue to shed oocysts (3). Furthermore, this ELISA has been used to detect C. parvum oocysts in diarrhoeic faeces from llamas and young horses with severe combined immunodeficiency (3).
COMPETITIVE INHIBITION ELISA
In addition to the detection of parasites during clinical stages of infection, it is also necessary to identify animals which have survived clinical disease and which are persistent carriers. Parasite levels in carrier animals are often too low to be detected by antigen capture ELISA; however, specific antibody is often maintained at detectable levels. First described for use in detecting anti-bluetongue virus antibody (2), the MAbbased competitive inhibition ELISA (C-ELISA) format has been used to detect antibodies to Cowdria ruminantium, A. marginale and Babesia equi (10, 11, 24) . A C-ELISA for detection of bovine anti-bluetongue virus antibody is commercially available (18) .
Components of the C-ELISA include a MAb and the corresponding epitope. The MAb must possess an appropriate binding affinity such that polyclonal antibody can replace it in the competitive reaction. Desirable epitope characteristics include a linear peptide composition, immunodominance, and conservation among isolates. The latter is an important characteristic in cases where production of the epitope by molecular cloning and expression in bacteria is necessary. Since the specificity of the C-ELISA depends entirely on the MAb used, the test is well suited for use with recombinant antigens. If the recombinant antigen is expressed in sufficient quantity to provide an appropriate signal:noise ratio after application to the ELISA plate as a bacterial lysate, additional purification of the recombinant antigen is not necessary.
The complement fixation (CF) test is currently the official test for anti-ß. equi antibodies in many countries, including the United States of America (5, 6, 8) . However, the test still has a number of limitations, as follows: a) CF cannot be used to test sera with anti-complement activity or sera which react with the control erythrocyte antigen used in the test b) sera containing specific IgG(T) antibody may yield false-negative results because IgG(T) does not fix complement by the classical pathway (14) c) the CF test has been shown to yield variable results in persistently-infected horses (7).
A MAb-based C-ELISA for detection of equine anti-B. equi antibodies has been described recently (11) . The format of this ELISA is illustrated in Figure 2 . This C-ELISA uses an IgGl MAb which binds to a peptide epitope on the surface of B. equi merozoites (12) . A concordance of 94% was found when 154 sera from 19 countries were tested by the C-ELISA and CF (11) . In this study, sera yielding discrepant results between the CF test and C-ELISA were retested by immunoprecipitation of 35S-methionine-labelled in vitro translation products of messenger ribonucleic acid from B. equi (11, 12) . Immunoprecipitation results indicated that sera which tested negative by CF and positive by C-ELISA were positive for B. equi (11) . The C-ELISA was shown to be specific for anti-B. equi antibody, as horses infected with B. caballi tested When equine test serum contains specific antibody, the specific equine antibody competes with the mouse MAb, thus decreasing the optical density (OD) to significantly below the level given by the negative reference serum, and the equine serum is considered positive. When the equine test serum does not contain specific antibody, the mouse monoclonal antibody binds to the epitope, thus yielding an increased optical density equivalent to negative reference serum, and the equine serum is considered negative negative (11) . The advantage of the C-ELISA is that the format overcomes limitations a) and b) listed above. Furthermore, the B. equi protein bearing the epitope used in the C-ELISA has been molecularly cloned and expressed in Escherichia coli, and the C-ELISA has been reformatted with this antigen (13) .
Recently, a highly-conserved A. marginale major surface protein (MSP-5) was described (24) . In preliminary testing, MSP-5 and a corresponding MAb successfully detected anti-A marginale antibody in immune bovine sera (24) . In addition, another A. marginale major surface protein (MSP-3) has demonstrated potential as a diagnostic antigen in the detection of anti-A marginale antibody in the sera of long-term carrier cattle (15) .
CONCLUSIONS
MAb-based ELISAs have tremendous potential for use in the diagnosis of parasitic diseases. The antigen capture ELISA can directly detect the presence of a parasite during the clinical stages of disease when treatment is most efficacious, and the C-ELISA format can be used to detect carriers of persistent parasitic infections. A final and important attribute of the C-ELISA is the ease with which it can be used with recombinant antigens. This is especially important in those parasitic diseases for which diagnostic antigen cannot yet be produced in cell culture. Furthermore, the production of recombinant antigen in E. coli precludes the necessity of infecting animals for antigen production. PALABRAS CLAVE: Anaplasma marginale -Babesia equiCryptosporidium parvum -Proteínas recombinantes -Pruebas de competición/inhibición ELISA -Pruebas de inmunocaptura ELISA -Virus de la fiebre catarral ovina. *
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